Onconova Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

* Onconova Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on March 18 (estimated) for the period ending December 31 2023

* The Newtown Pennsylvania-based company is expected to report a 16.7% increase in revenue to $65.33 thousand from $56 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Onconova Therapeutics Inc is for a loss of 25 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Onconova Therapeutics Inc is $7.00​, above​ its last closing price of $0.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Sep. 30 2023 -0.29 -0.29 -0.23 Beat 20.7

Jun. 30 2023 -0.31 -0.31 -0.20 Beat 36

Mar. 31 2023 -0.30 -0.30 -0.28 Beat 5.9​

Dec. 31 2022 -0.28 -0.26 Beat 7.1

​​Sep. -0.21 -0.21 -0.26 Missed -22.4

30 2022

Jun. 30 2022 -0.21 -0.20 -0.19 Beat 3.8​

Mar. 31 2022 -0.19 -0.19 -0.20 Missed -5.3

Dec. 31 2021 -0.20 -0.27 -0.15 Beat 44.4

This summary was machine generated March 15 at 20:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)